App-Quantinova.ai

Phase 3, randomized, double-blind trial of pembrolizumab plus epacadostat or placebo for cisplatin-ineligible urothelial carcinoma (UC): KEYNOTE-672/ECHO-307.

Arjun Vasant Balar - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

Pembrolizumab (pembro) plus epacadostat or placebo for locally advanced or metastatic urothelial carcinoma (UC) after failure of first-line platinum-containing chemotherapy: KEYNOTE-698/ECHO-303.

Thomas Powles - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Pembrolizumab

Clinical parameters predicting response and outcomes to immunotherapy in metastatic cancers.

Rohan Garje - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

Pushing the accelerator and releasing the brake: A phase I dose escalation study evaluating a LAG-3 fusion protein (eftilagimod alpha), together with pembrolizumab in unresectable or metastatic melanoma.

Melissa A. Eastgate - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

Prevalence of microsatellite instability and association with pembrolizumab (P) usage in a real-world clinico-genomic database.

Claire O'Connell - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Pembrolizumab

Efficacy and safety profile of PD-1 and pdl-1 inhibitors in African American patients.

Shahla Bari - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

Impact of comorbidity on immune checkpoint blockade tolerance across tumor types.

Sean Clark-Garvey - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

A review of the patterns of prescribing, efficacy and toxicities for patients receiving checkpoint inhibitors.

Peter Nightingale - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Pembrolizumab

Dynamic testing of positive and negative biomarkers on peripheral blood cells at early stages of immunotherapy predicts response in advanced cancer patients.

Wushuang Du - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

A single-institution study of renal outcomes in patients receiving checkpoint inhibitors.

Sarah Mushtaq - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

Evaluation of tumor biomarkers in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer treated with the CXCL12 inhibitor NOX-A12 and preliminary safety in combination with PD-1 checkpoint inhibitor pembrolizumab.

Niels Halama - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

Retrospective review of immune checkpoint inhibitor therapy (ICI) at the Michael E. DeBakey VA Medical Center Cancer Center (MEDVAMCCC).

Jan Ole Kemnade - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

A longitudinal retrospective case series of the real-world toxicities encountered among cancer patients receiving anti-PD-L1 checkpoint inhibitor immunotherapy.

Anastasios L. Boutis - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

Retronectin and anti-CD3 monoclonal antibody actived T cell combined anti-PD-1 therapy in heavy-treated renal cell cancer.

Ling-Di Zhao - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Pembrolizumab

PD-1 inhibition in cutaneous squamous cell carcinoma (cSCC).

David Jacob Hermel - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

Monitoring of thyroid function test abnormalities in cancer patients undergoing immune checkpoint inhibitor therapy in a community based cancer center.

Mehmet Sitki Copur - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

Mapping PD-1 inhibitors side effects using patient-reported outcomes (PRO) generated by a digital patient-powered network (PPN).

Daniel A. Vorobiof - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Pembrolizumab

Immunotherapy in advanced cancers and predictor factors for outcome: An Indian experience.

Kushal Gupta - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

Adoption rates of immune checkpoint inhibitors in real world oncology practice.

Jennifer O. Nwankwo - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

Novel anti-PD-1 antibodies not acting through PD-1/pdl-1 blockade that enhance tumor clearance.

Craig Fenwick - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Pembrolizumab

Filters

2307 Abstracts